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Abstract The interaction between oxaliplatin and the
model protein ubiquitin (Ub) was investigated in a top–
down approach by means of high-resolution electrospray
ionization mass spectrometry (ESI-MS) using diverse
tandem mass spectrometric (MS/MS) techniques, including
collision-induced dissociation (CID), higher-energy C-trap
dissociation (HCD), and electron transfer dissociation
(ETD). To the best of our knowledge, this is the first time
that metallodrug–protein adducts were analyzed for the
metal-binding site by ETD-MS/MS, which outperformed
both CID and HCD in terms of number of identified
metallated peptide fragments in the mass spectra and the
localization of the binding sites. Only ETD allowed the
simultaneous and exact determination of Met1 and His68
residues as binding partners for oxaliplatin. CID-MS/MS
experiments were carried out on orbitrap and ion cyclotron
resonance (ICR)-FT mass spectrometers and both instru-
ments yielded similar results with respect to number of
metallated fragments and the localization of the binding
sites. A comparison of the protein secondary structure with
the intensities of peptide fragments generated by collisional
activation of the [Ub+Pt-(chxn)] adduct [chxn=(1R,2R)-
cyclohexanediamine] revealed a correlation with cleavages
in solution phase random coil areas, indicating that the N-
terminal β-hairpin and α-helix structures are retained in the
gas phase.
Keywords Anticancer metallodrugs . Tandem mass
spectrometry . Electron transfer dissociation . Oxaliplatin .
Ubiquitin
Introduction
Platinum-based chemotherapeutics such as cisplatin, carbo-
platin, and oxaliplatin play an important role in cancer
treatment. To exert their therapeutic effects, platinum-based
anticancer drugs primarily target cellular DNA [1]. However,
prior to entering the cell, plasma proteins also constitute
excellent binding partners and it was found that Pt(II)-based
metallodrugs bind to human serum albumin (HSA) and other
plasma proteins upon administration [2, 3]. Furthermore, it is
thought that the interaction with proteins accounts at least
partially for the deactivation of these therapeutic agents and
also for some adverse side effects observed during chemo-
therapy of cancer patients [4]. Understanding the binding to
biomolecules is thus crucial for the development of novel
metal-based anticancer drugs with enhanced selectivity and
reduced side effects, however, the preferred binding sites of
the Pt(II)-based anticancer drugs on proteins are still a matter
of debate [5–8].
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The identification of binding sites and of the nature of
metallodrug–protein interactions both with clinically ap-
proved metal-based anticancer agents and also with develop-
mental metallodrugs have been attempted using a wide range
of bioanalytical and biophysical methods [9, 10]. Several off-
and on-line mass spectrometric (MS) methods have proven
to be powerful tools for the characterization of metallodrug–
biomolecule interactions [11]. Electrospray ionization (ESI)
and MALDI have been used to study various systems
including in vitro binding studies to both DNA and proteins
[8, 12–14], and even whole cells were treated with cisplatin,
digested, and analyzed [15, 16]. The ability of metallodrugs
to form adducts with plasma and cytoplasmic proteins such
as HSA [8, 17, 18], myoglobin [19], transferrin [5, 20],
model interactions with peptides [21, 22], and small model
proteins such as ubiquitin (Ub) [11, 19, 23, 24],
cytochrome-c (cyt-c) [25], lysozymes [7], and oligonucleo-
tides [22, 26] have been subject of investigation by various
MS methods.
In classical proteomics, bottom–up methodologies are
widely used to characterize and identify protein sequences
by analysis of enzymatic digests of proteins based on their
mass fingerprints [27–29]. While bottom–up methods
remain the best option for large proteins, they should
cautiously be applied when investigating metallodrug–
protein interactions since these may be prone to metal-
lodrug cleavage during enzymatic digestion. More recently,
top–down strategies were introduced [30], offering reduced
experimental complexity and the ability to characterize
entire protein sequences, whilst retaining post-translational
modifications (PTMs) or even allowing the study of non-
covalent interactions [31]. Considering metallation as a
special type of PTM, top–down MS should be the method
of choice for the detailed characterization of metallodrug–
biomolecule conjugates [32]. Binding site localization can
be achieved by tandem mass spectrometric methods, which
include collision-induced dissociation (CID) [33], higher-
energy C-trap dissociation (HCD) [34], infrared multipho-
ton dissociation [35], electron transfer dissociation (ETD)
[36], or electron-capture dissociation (ECD) [37–39] and
often deliver complementary information. CID and HCD
are similar fragmentation methods relying on the collision
of the molecules with inert gas molecules, which in turn
leads to protein backbone cleavage, specifically at the
amide C–N bond to produce predominantly b- and y-
peptide fragments. Collisions with low-energy CID are less
energetic than by HCD. Fragmentation by ECD and ETD is
based on the transfer of electrons, which results in softer
and more random protein backbone cleavages at N–Cα
bonds and produces mainly c- and z-type peptide frag-
ments. These methods have rarely been employed in studies
on metal-based anticancer agents and therefore, we report
here a comparative study on the binding site characteriza-
tion of oxaliplatin bound to Ub using different fragmenta-
tion methods in combination with high-resolution mass
spectrometry. Oxaliplatin is the latest of the clinically
approved platinum-based anticancer agents and compared
with cisplatin, there are only a few investigations on
binding interactions of this compound with biomolecules.
The 76-amino acid protein Ub was established as a model
in metallodrug binding studies [11, 19, 23, 24, 40] and
Met1 has been characterized as a binding partner for
cisplatin [24] and His68 being believed to represent the
second binding site.
Experimental
Materials and methods
Ub (from bovine red blood cells, min 90%) was purchased
from Sigma (Vienna, Austria), oxaliplatin from Sequoia
Research Products (Pangbourne, UK), trifluoroacetic acid
(98%) from Fluka (Vienna, Austria), and methanol (HiPer-
Solv CHROMANORM) from VWR (Vienna, Austria). All
materials from chemical suppliers were used as received.
MilliQ water was obtained from a Millipore Synergy 185
UV Ultrapure apparatus (18.2 MΩ). Oxaliplatin and Ub
were incubated in a molar ratio of 2:1 in water (pH 5.5) for
7 days at 37 °C. The reaction mixture was diluted with
water/methanol/trifluoroacetic acid (50:50:0.1) to yield a
final protein concentration of 1–5 μM, i.e., measurements
were performed under denaturing conditions.
Instrumentation
LTQ Velos Orbitrap MS Incubation mixtures of oxaliplatin
and Ub were introduced by direct infusion into the ESI
source of the mass spectrometer at a flow rate of 5 μL/min.
Survey and tandem mass spectra were recorded on a hybrid
LTQ Velos Orbitrap mass spectrometer (Thermo Scientific,
Bremen, Germany) employing CID-, HCD-, and ETD-MS/
MS. Additional experimental settings were as follows:
source voltage, +4 kV; source temperature, 40 °C; capillary
temperature, 250 °C; sheath gas flow, 10 L/min; minimal
signal required, 500; and isolation width, 10 Th. The
normalized collision energies during MS/MS experiments
were 30%, 40%, and 8% for CID, HCD, and ETD,
respectively. Data were processed with Xcalibur 2.1
software (Thermo Scientific).
FT-ICR MS Incubation mixtures of oxaliplatin and Ub (ca.
3 μM) were introduced by direct infusion via an ESI source
into a 9.4-T mass spectrometer (Bruker Daltonics GmbH,
Bremen, Germany) with a flow rate of 0.5 μL/min. CID-
MS/MS measurements were performed with 10 ms accu-
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mulation time in the external quadrupole-based collisional
cell. Additional instrument settings were as follows:
capillary entrance voltage, −1.5 kV; capillary exit voltage,
+100 V; dry gas flow rate, 35 L/min; dry gas temperature,
200 °C; scan width, m/z 400–3,000; extraction voltage for
ESI, −10 V; and nebulizing gas flow rate, 30 L/min. Spectra
were acquired using Apex Control II. Data were analyzed
and processed by ESI Compass 1.3 and Data Analysis 4.0
software (Bruker Daltonics).
Results and discussion
Characterization of oxaliplatin–Ub adducts by broadband
ESI-MS
Oxaliplatin/Ub mixtures were incubated under non-denaturing
conditions at pH 6, which reflect conditions that exist in
hypoxic tumorigenic tissue [41, 42]. The incubation mixture
was diluted to 1–5 μM (protein) with H2O/MeOH/TFA,
causing denaturation of the protein to improve fragmentation
efficiencies, and the samples were immediately injected into
the ESI source of the mass spectrometer.
Platinum-based anticancer agents may interact with bio-
molecules at different stages of their activation process [43].
Oxaliplatin was designed to exhibit a very slow hydrolysis
rate with a view to reduce unwanted side effects. Indeed,
analysis of the reaction mixture containing a twofold excess
of oxaliplatin by ESI-MS showed ∼50% free Ub after
incubation for 7 days. The activation mechanism of
oxaliplatin rendering it capable of binding to biological
molecules is thought to involve two successive steps.
Initially, one bond between platinum and the oxalato
chelating ligand is hydrolyzed forming a mono-aqua
complex, after which cleavage of the remaining platinum-
oxalato bond and ligand release from the platinum center
occurs (Scheme 1). Therefore, several Pt–Ub derivatives
were observed in the deconvoluted mass spectrum (Fig. 1)
with the most prominent corresponding to an oxaliplatin–Ub
adduct at m/z 8,871.704 (84% relative intensity to free Ub;
all relative intensities refer to the most abundant peak in the
respective mass spectrum). This signal can be assigned to a
mono-adduct consisting of Ub and a Pt(chxn) moiety (chxn=
(1R,2R)-cyclohexanediamine) having undergone cleavage of
the oxalato ligand. Further identified species include the
mono-adduct after the first activation step [Ub+(ox)Pt
(chxn)]+ (m/z 8,961.697, 10%; oxalate (ox)), as well as
higher adducts such as [Ub+2Pt(chxn)]+ (m/z 9,177.582,
24%) and [Ub+Pt(chxn)+(ox)Pt(chxn)]+ (m/z 9,268.751,
11%). The existence of platinum species stemming from
the initial hydrolysis step was reported previously [43], and
these findings provide further support for a two-step
activation mechanism.
Comparative tandem mass spectrometry of oxaliplatin–Ub
adducts
Top–down tandem mass spectrometric experiments on the
incubation mixture were performed to directly identify
binding sites of oxaliplatin on Ub using different fragmen-
tation methods. These investigations were carried out with
the most abundant adduct identified in the broadband mass
spectrum, i.e., [Ub+Pt(chxn)]. The 12+ charge state (m/z
740.313) was selected for binding site characterization in
the orbitrap FT MS-based experiments and, for comparison,
the 11+ charge stage (m/z 807.515) in the FT-ICR MS-
based experiments. The employment of charge states larger
than 10+ implies that Ub is entirely denatured and
protonated to a large degree. CID-MS/MS was performed
on both orbitrap- and ICR-FT MS instruments, whereas
HCD- and ETD-MS/MS were performed on the orbitrap
mass spectrometer only.
CID-MS/MS fragmentation profiles were comparable on
both instruments and similar metallated peptide fragments
were found. While the platinated peptide fragments were
generally more abundant using FT-ICR MS, a higher
number of such fragments was identified with the orbitrap
MS approach. For the [Ub+Pt(chxn)] adduct, CID led to
the characterization of 23 different metallated peptide
fragments for the orbitrap MS, compared to 15 with the
FT-ICR MS. Assignable platinated peptide fragment ions
Scheme 1 Hydrolysis of oxaliplatin is responsible for activation of the prodrug and involves two successive steps (ox oxalate, chxn (1R,2R)-
cyclohexanediamine). Upon hydrolysis, oxaliplatin may more readily react with to suitable biological binding partners
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were found over a broad mass (especially m/z 700–1,000)
and charge (1+ to 11+) range with a resolution of
R≈120,000 at m/z 567.171 (Pt(chxn)B2+) for both instrument
types (Fig. 2). The mass accuracy of the metallated
fragments was in general <1 ppm.
Since bis-platinated Ub adducts were observed in
significant intensities in the survey mass spectra, at least
two main binding sites are to be expected for the [Ub+Pt
(chxn)] adducts. Indeed, the Pt(chxn)-containing peptide
fragments detected by CID-MS/MS indicated two possible
binding sites. The former was identified as N-terminal Met1
based on the Pt(chxn)B2
+ ion (the following annotation
system was used throughout the text to describe platinated
peptide fragments: capital letters indicate metallated frag-
ments, analogous to the conventional peptide ion type
nomenclature. The nature of the bound metal species is
given as preceding superscript; e.g., Pt(chxn)B2
+ stands for
the Pt(chxn) moiety bound to the b2-fragment of Ub in
charge state 1+) as the smallest metal-containing peptide
fragment, identified on both instruments and also observed
earlier [23]. In addition, high molecular weight fragments,
such as the b2 complementary metallated fragment
Pt
(chxn)Y74
10+/11+, indicate the presence of a second binding
site. Several C-terminal metallated peptide fragments were
detected with both instruments. They range from Pt
(chxn)Y24
5+ to Pt(chxn)Y75
11+ on the orbitrap FT MS and
from Pt(chxn)Y18
3+ to Pt(chxn)Y74
10+ on the FT-ICR MS.
These fragments do not give the exact location of the
second binding site, but they do reveal that it must be
within the last 18 residues of the C-terminal protein
sequence. Most of the B- and Y-fragments are centered
around y58, which was observed in all collisionally
activated tandem mass spectra, i.e., Pt(chxn)B16
2+, and also
the complementary peptide fragment y60
8+ (m/z 845.833,
1%) was detected.
HCD is a fragmentation technique that makes use of
higher-energy collisions and generally results in increased
fragmentation efficiency and sequence coverage. Indeed, 27
metallated fragments were unambiguously identified in the
HCD-orbitrap MS/MS experiments. In addition, higher-
energy collisions yielded a fragmentation profile where the
metallated peptide fragments were generally smaller and of
lower charge than with CID-orbitrap MS/MS. N- and C-
terminal metallated fragments were essentially equal in
intensity and number. HCD gave rise to metallodrug–
peptide fragments with higher relative intensities compared
with CID and with similar resolution and mass accuracies
of <1 ppm (Fig. 3a).
Fig. 1 Deconvoluted FT-ICR mass spectrum of the oxaliplatin/Ub
incubation mixture after 7 days in the region m/z 8,400–9,600.
Oxaliplatin and Ub were reacted in a molar ratio of 2:1. The most
abundant adduct corresponds to [Ub+Pt(chxn)]
Fig. 2 (a) CID-orbitrap- and (b)
CID-ICR-FT tandem mass
spectra of the [Ub+Pt(chxn)]
adduct. Oxaliplatin and Ub were
reacted in 2:1 molar ratio and
incubated for 7 days. The two
most probable binding partners,
i.e., Met1 and His68, are under-
lined in the amino acid sequence
of Ub. Bars between the se-
quence letters refer to metallated
peptide fragments
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Many metallated N-terminal fragments were detected,
ranging from Pt(chxn)B2
+ to Pt(chxn)B18
3+, also confirming
Met1 as the primary binding site for oxaliplatin. With regard
to the second binding site of oxaliplatin, small platinated
and non-platinated C-terminal fragments were analyzed.
Indeed, the HCD tandem mass spectrum contained signals
assignable to non-metallated y8
2+ ions, as well as metal-
lated Pt(chxn)Y13
2+, Pt(chxn)Y14
2+ and Pt(chxn)Y15
2+ fragments.
This finding narrowed the number of possible binding sites
to a 5-amino acid sequence containing Glu64 and His68 as
most nucleophilic sites. In contrast to CID where comple-
mentary fragments were found at several points along the
protein sequence, the only observable complementary pair
was the Pt(chxn)B18
3+/y58
8+ couple.
In parallel to collision-induced fragmentation techniques,
the [Ub+Pt(chxn)] adduct was subjected to ETD. This
fragmentation method, based on ion/ion reactions resulting
in electron transfers, leads to N–Cα bond breaks along the
peptide backbone and specifically yields c- and z-fragment
ions. The general advantage of ETD is that it retains PTMs
to a large extent, making it a valuable tool for top–down
protein sequencing in proteomics. In addition, electron
transfer should result in a more random fragmentation
pattern relative to collisionally induced fragmentation
techniques.
ETD-MS/MS generated a very different fragmentation
profile in comparison to collisionally activated fragmentation
methods (Fig. 3b). Even though the relative intensities and
the resolution (R≈120,000 at m/z 586.785 [Pt(chxn)C72+]) of
the platinated peptide fragments were similar to those
obtained by CID and HCD methods, ETD allowed identify-
ing a higher number of metallated fragments, i.e., 50 in total,
which represents the highest value among the different
fragmentation techniques. A total of 46 N-terminal platinated
fragments were detected ranging from Pt(chxn)C2
+ to
Pt(chxn)C75
8+, thus verifying Met1 as the first binding partner
of oxaliplatin on Ub. The most abundant metal-containing
fragment was identified as Pt(chxn)C59
7+ (21%), as opposed to
Pt(chxn)B18
2+/3+ for collisionally activated methods, which
may be related to the different fragmentation mechanisms. It
is believed that positively charged amino acids act as
electron scavengers during electron transfer [44]. In the case
of Ub, Lys48 is in close proximity to the peptide bond
between Tyr59 and Asn60. This may facilitate backbone
cleavage and be responsible for the high abundance
observed. In addition, collisionally induced fragmentation
at Glu18 may also produce very stable products, i.e., in
source generation of y58 is known. On the other hand, C-
terminal metallated peptide fragments ranged from
Pt(chxn)Z10
2+ to Pt(chxn)Z45
6+. The metallated Pt(chxn)Z10
2+ and
non-metallated z8
2+ C-terminal fragments clearly identify the
second binding site as His68 excluding Glu64 as a potential
binding partner. ETD therefore emerges as a superior
fragmentation technique to CID and HCD when investigat-
ing metallodrug–protein adducts via a top–down approach
both in terms of fragment numbers and localization of
binding sites. It is the only fragmentation technique that
allowed the simultaneous identification of both Met1 and
His68 as binding partners from a single precursor. The lower
efficiency of CID- and HCD-MS/MS for detecting metal-
lated peptides might be due to collision-induced gas phase
demetallation, whereas ETD-MS/MS is a softer fragmenta-
tion technique and might retain coordinative Pt-protein
bonds to a larger degree.
A striking observation is the large discrepancy between
the number of C- and Z-fragments (46:4). One explanation
Fig. 3 (a) HCD-orbitrap- and
(b) ETD-orbitrap tandem mass
spectra of the [Ub+Pt(chxn)]
adduct. Oxaliplatin and Ub were
reacted in 2:1 molar ratio and
incubated for 7 days. The two
most probable binding partners,
i.e., Met1 and His68, are under-
lined in the amino acid sequence
of Ub. Solid bars between the
sequence letters refer to detected
metallated peptide fragments
whereas the dashed bars refer to
the y8 and z8 fragments
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might involve favored binding of oxaliplatin to the N-
terminal Met1 which causes a higher abundance of such
fragments compared with C-terminal His68. In support of
this hypothesis is the fact that the number of characterized
z-fragments during ETD measurements on bare Ub is
approximately three times higher than the respective c-
fragments. Therefore, Met1 is considered the primary
binding site of oxaliplatin on Ub.
Insights into the secondary structure of the [Ub+Pt(chxn)]
adduct
ESI mass spectrometry is extensively used to gain informa-
tion on the higher order structure of proteins, in particular in
the elucidation of the tertiary structure. For this purpose,
several approaches have proven effective, the most wide-
spread being H/D-exchange [45, 46], covalent labeling [47],
and ion mobility MS [24, 48]. The tertiary protein structure
is affected by the solvent conditions employed during
incubation and infusion into the mass spectrometer [49,
50]. Importantly, a correlation between charge state (i.e.,
unfolding), temperature and fragmentation efficiency has
been established [51]. In contrast to tertiary structure, only a
few experiments were conducted on protein secondary
structures by means of ESI mass spectrometry. Secondary
structures are supposed to remain, to some degree, intact
under denaturing conditions but it is unknown if the same
secondary structures are retained in the gas phase as present
in solution [49, 51–54].
In the present study, MS/MS experiments were per-
formed under denaturing conditions which led to breakdown
of the protein tertiary structure. When the protein transfers
from solution to the gas phase at the ESI interface,
hydrophobic interactions are further diminished and elec-
trostatic effects enhanced, resulting in the protein adopting a
near-linear conformation [51]. Secondary structures are
stabilized by H-bonding in the gas phase and presumably
more energy is required in collisionally activated fragmen-
tation experiments to cleave the protein backbone at these
locations compared to random coil sequences. Interestingly,
plotting the MS/MS-fragment intensities from the combined
CID and HCD data sets relative to the sequence revealed a
strong correlation with solution random coil structures
(Fig. 4) [55]. The backbone cleavages suggest that the N-
terminal β-hairpin section stays intact. The random coil
sequence Val17–Thr22 connects the β-hairpin with the only
α-helix in Ub and from Glu16–Ile23, six out of eight
peptide bond cleavages were observed. The section of the
α-helix remained intact to a large degree. The next cleavage
occurred prior to the successive prolines at positions 36/37,
which initiate the α-turn. The subsequent β-strand is
followed by an extended random coil sequence, which
displays four consecutive cleavages from Gln49–Asp52.
The remaining α-turn and β-strand sections are not
sufficiently stabilized when the protein adopts a near-linear
conformation and therefore, numerous cleavages occur
between Asp58 and Glu64. These results suggest that
solution secondary structures of the [Ub+Pt(chxn)] adduct
are retained to a considerable extent in the gas phase.
Contrary to CID and HCD methods, ETD did not yield such
pronounced specificity because it generates more random
cleavages on the protein backbone (Fig. 4).
Conclusions
This work highlights the application of high-resolution
mass spectrometric methods for top–down characterization
of metallodrug–protein adducts. The major adduct of
oxaliplatin at Ub is formed with a Pt(chxn) moiety. In
addition, the experimental setup yielded further adduct
types, which were identified as [Ub+(ox)Pt(chxn)], [Ub+
2Pt(chxn)], and [Ub+Pt(chxn)+(ox)Pt(chxn)] in support of
a two-step activation mechanism of oxaliplatin. ESI
Orbitrap- and ICR-FT MS combined with CID-, HCD-,
and ETD-MS/MS data were used to locate the binding sites
of oxaliplatin on Ub. All fragmentation experiments were
carried out under denaturing conditions and analyzed in
high charge states in order to maximize fragmentation
efficiency. ETD yielded the highest number of metallated
Fig. 4 A combined plot of backbone cleavage sites (bars) depending
on decreasing relative intensities observed during CID- and HCD-MS/
MS experiments with the [Ub+Pt(chxn)] adduct. The last row features
cleavages from the ETD-MS/MS experiment. The positions of the
secondary structures were determined by the Kabsch–Sanders algo-
rithm. White background refers to random coil sequence areas
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fragments and was the only technique to unequivocally
establish Met1 and His68 as the two binding sites for
oxaliplatin on Ub. From this study, ETD has emerged as a
powerful method for characterizing metallodrug–protein
binding sites. On the other hand only collisionally activated
methods yielded insights into the secondary structure of
Ub. In particular, a correlation was found between peptide
fragments and cleavage at random coil sequences, indicat-
ing that β-hairpin and α-helix structures of the [Ub+Pt
(chxn)] adduct are retained in the gas phase.
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